Study Finds Steroid Therapy Benefits Patients with Pneumonia

Article

McMaster University research, published online today by the Annals of Internal Medicine, has demonstrated the benefits of corticosteroid therapy for one of the most common serious medical conditions.

“Our study should lead to an important change in treatment for pneumonia,” said lead author Dr. Reed Siemieniuk, a physician and a graduate student at McMaster University. “Corticosteroids are inexpensive and readily available around the world. Millions of patients will benefit from this new evidence.”

Lower respiratory infections are the second most common cause of premature mortality globally. In developed countries, hospitalization for community-acquired pneumonia is common and is often associated with acute respiratory distress syndrome requiring mechanical ventilation and with significant mortality.

The research, led by investigators of McMaster’s Michael G. DeGroote School of Medicine and including a number of international collaborators, summarized the evidence from 13 randomized trials involving more than 2,000 patients.

Evidence showed patients with community-acquired pneumonia who received corticosteroids were discharged from hospital one day sooner. Results also suggested that corticosteroid treatment reduces the need for mechanical ventilation (or the requirement for a breathing tube) from 9 percent to 5 percent of patients; and the likelihood of a life-threatening complication called acute respiratory distress syndrome from 8 percent to 2 percent of patients. The results also raised the possibility of a significant reduction in death rates from 9 percent to 10 percent of patients, down to 5 percent to 6 percent.

“Seldom do we see a major advance in treatment of a condition as common as community-acquired pneumonia,” says Dr. Gordon Guyatt, the study’s senior investigator and a professor of clinical epidemiology and biostatistics at McMaster.

“Corticosteroids over short periods are safe, and we now know that they achieve important benefits in a serious and common medical illness.”

Source: McMaster University  

Recent Videos
Lindsay K. Weir, MPH, CIC, Lead Infection Preventionist/Infection Preventionist III
•	Rebecca (Bartles) Crapanzano-Sigafoos, DrPH, MPH, CIC, FAPIC (corresponding author), executive director of APIC’s Center for Research, Practice, and Innovation, and lead author of the study.
Infection Control Today's Infection Intel: Staying Ahead With Company Updates and Product Innovations.
COVID-19 presentations at IDWeek in Las Angeles, California by Invivyd.   (Adobe Stock 333039083 by Production Perig)
Long COVID and Other Post-Viral Syndromes
Meet Jenny Hayes, MSN, RN, CIC, CAIP, CASSPT.
Infection Control Today Editorial Advisory Board: Fibi Attia, MD, MPH, CIC.
Andrea Thomas, PhD, DVM, MSc, BSc, director of epidemiology at BlueDot
mpox   (Adobe Stock 924156809 by Andreas Prott)
Meet Alexander Sundermann, DrPH, CIC, FAPIC.
Related Content